Abstract
Treatment with analogues of the SERCA-inhibitor Thapsigargin is a promising new approach for a wide variety of cancer entities. However, our previous studies on various tumor cells suggested resistance of SEC62 over-expressing tumors to this treatment. Therefore, we proposed the novel concept that e.g. lung-, prostate-, and thyroid-cancer patients should be tested for SEC62 over-expression, and developed a novel therapeutic strategy for a combinatorial treatment of SEC62 over-expressing tumors. The latter was based on the observations that treatment of SEC62 over-expressing tumor cells with SEC62-targeting siRNAs showed less resistance to Thapsigargin as well as a reduction in migratory potential and that the siRNA effects can be mimicked by the Calmodulin antagonist Trifluoperazine. Therefore, the combinatorial treatment of SEC62 over-expressing tumors was proposed to involve Thapsigargin and Trifluoperazine. Here, we addressed the impact of Thapsigargin and Trifluoperazine in separate and combined treatments of heterotopic tumors, induced by inoculation of human hypopharyngeal squamous cell carcinoma (FaDu)-cells into the mouse flank. Seeding of the tumor cells and/or their growth rate were significantly reduced by all three ...Continue Reading
References
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·M M Tomayko, C P Reynolds
May 9, 2000·The Journal of Biological Chemistry·H A MeyerE Hartmann
Jun 22, 2000·Proceedings of the National Academy of Sciences of the United States of America·J TyedmersR Zimmermann
Dec 14, 2001·Journal of Medicinal Chemistry·C M JakobsenS B Christensen
Jul 3, 2003·Journal of the National Cancer Institute·Samuel R DenmeadeJohn T Isaacs
Feb 19, 2004·The Journal of Biological Chemistry·Cheng XuChikashi Toyoshima
Jan 22, 2005·Cancer Biology & Therapy·Samuel R Denmeade, John T Isaacs
Dec 29, 2005·Neuroscience Letters·Lei TangZaijie Jim Wang
Apr 28, 2007·Organic & Biomolecular Chemistry·Stephen P AndrewsSteven V Ley
May 7, 2009·Molecular Cancer Therapeutics·Donald J Vander GriendJohn T Isaacs
Jan 15, 2010·Molecular Biology of the Cell·Linda MüllerRichard Zimmermann
Jul 30, 2010·International Journal of Cancer. Journal International Du Cancer·Markus GreinerRichard Zimmermann
Nov 26, 2010·The EMBO Journal·Frank ErdmannRichard Zimmermann
Mar 17, 2011·Channels·Sven LangRichard Zimmermann
May 11, 2011·The Prostate·Markus GreinerBernd Wullich
May 12, 2011·Channels·Anke HarsmanMartin Jung
Dec 27, 2011·The American Journal of Pathology·Maximilian LinxweilerMarkus Greiner
Jul 17, 2012·The EMBO Journal·Nico SchäubleRichard Zimmermann
Aug 10, 2013·The FEBS Journal·Charlotte DuboisJesper V Møller
Dec 7, 2013·BMC Cancer·Maximilian LinxweilerMarkus Greiner
Jul 30, 2014·Steroids·Nhu Thi Quynh DoanSøren Brøgger Christensen
May 16, 2015·PloS One·Hai-long WangZhi Guo
Nov 18, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Silke WemmertBernhard Schick
Apr 27, 2016·British Journal of Cancer·D MahalingamM Carducci
Sep 7, 2016·Lancet·Fred R HirschPaul A Bunn
Citations
Jan 14, 2020·Journal of Chemotherapy·Xue-Jun WangMei-Juan Yan
Jul 23, 2020·Bioscience Reports·Bo TangYu Tu
Sep 27, 2018·Frontiers in Cell and Developmental Biology·Ioanna DaskalakiNektarios Tavernarakis
May 1, 2021·Cells·Mark SickingMaximilian Linxweiler
May 1, 2021·Cancers·Cornelia S L MüllerMaximilian Linxweiler
Dec 9, 2020·Journal of Medicinal Chemistry·Yulin Ren, A Douglas Kinghorn
May 13, 2021·Visceral Medicine·Markus CasperSusanne N Weber